يعرض 1 - 20 نتائج من 146 نتيجة بحث عن '"de Elisabeth G. E. Vries"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
  2. 2

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Translational Immunology Groningen (TRIGR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

    المصدر: Annals of Oncology, 27(Supplement 1), i23-i29. Oxford University Press

  3. 3
  4. 4
  5. 5
  6. 6

    المساهمون: Groningen Research Institute of Pharmacy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Nanotechnology and Biophysics in Medicine (NANOBIOMED)

    المصدر: British Journal of Cancer
    British Jounal of Cancer, 109(10), 2685-2695. Nature Publishing Group

    وصف الملف: application/pdf

  7. 7
  8. 8
  9. 9
  10. 10

    المساهمون: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Life Course Epidemiology (LCE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Groningen Research Institute for Asthma and COPD (GRIAC), Vascular Ageing Programme (VAP)

    المصدر: Annals of Oncology, 22(10), 2286-2293. Oxford University Press

  11. 11
  12. 12
  13. 13

    المساهمون: Medical oncology laboratory, CCA - Innovative therapy

    المصدر: Drug Resistance Updates, 13, 2-15. Churchill Livingstone
    Stegehuis, J H, de Wilt, L H A M, de Vries, E G, Groen, H J, de Jong, S & Kruyt, F A 2010, ' TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives ', Drug Resistance Updates, vol. 13, pp. 2-15 . https://doi.org/10.1016/j.drup.2009.11.001

  14. 14

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Public Health

    المصدر: European Journal of Cancer, 46(14), 2605-2616. ELSEVIER SCI LTD
    European Journal of Cancer, 46(14), 2605-2616. Elsevier Ltd.

  15. 15
  16. 16

    المساهمون: Human genetics, CCA - Oncogenesis, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON)

    المصدر: van der Groep, P, van Diest, P J, Menko, F H, Bart, J, de Vries, E G E & van der Wall, E E 2009, ' Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers ', Journal of Clinical Pathology, vol. 62, no. 10, pp. 926-930 . https://doi.org/10.1136/jcp.2009.065524
    Journal of Clinical Pathology, 62(10), 926-930. BMJ Publishing Group
    Journal of Clinical Pathology, 62(10), 926-930. BMJ PUBLISHING GROUP

  17. 17
  18. 18

    المساهمون: Obstetrics and gynaecology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D)

    المصدر: Eskens, F A L M, Mom, C H, Planting, A S T, Gietema, J A, Amelsberg, A, Huisman, H, Van Doorn, L, Burger, H, Stopfer, P, Verweij, J & De Vries, E G E 2008, ' A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours ', British Journal of Cancer, vol. 98, no. 1, pp. 80-85 . https://doi.org/10.1038/sj.bjc.6604108
    British Journal of Cancer
    British Journal of Cancer, 98(1), 80-85. Nature Publishing Group

  19. 19
  20. 20